Aileron Therapeutics Reports Cohort 1 Results from the P-Ib Study of LTI-03 for Idiopathic Pulmonary Fibrosis (IPF)
Shots:
- The P-Ib study assesses LTI-03's safety & tolerability vs PBO in IPF patients not previously treated with anti-fibrotic agents for at least 2mos.
- Cohort 1 evaluated 9 patients in the active arm & 3 in PBO arm who underwent bronchoscopy at baseline, were administered LTI-03 (2.5mg, BID) for 14 days & had bronchoscopy on D14 with 7 days of follow-up
- The results depicted reduced profibrotic protein expression in pathologic basal-like cells & fibroblasts, decreased levels of GAL-7, TSLP & Col-1α1 biomarkers confirming its ability of fibrosis & inflammation reduction and solRAGE stimulation without inducing inflammation in PBMCs. P-Ib study continues with top-line results of high-dose cohort anticipated in Q3’24
Ref: Aileron Therapeutics |Image: Aileron Therapeutics
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
